Drug

Platinum Compound

CI-DRUG-00000480Explore in graph →NCIt C1450 CIViC

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	2	2	0	2	0	—	—	Jul 16, 2019
Malignant Lung Neoplasm	Phase2	Phase 2	1	1	0	1	0	—	—	Nov 6, 2025

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 17 hours agoSource updated unknown

Curated evidence

Clinical evidence (15)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–15 of 15 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB2 Mutation1
Platinum Compound	Bladder Carcinoma

Clinical trials

Trials with this intervention (2)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–2 of 2 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03816345	Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO	recruiting	Phase 1	300	National Cancer Institute (NCI)NIH	2	Sep 23, 2026	clinicaltrials
NCT06769126	Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study	recruiting

EGFR Amplification1
Cetuximab + Fluorouracil + Platinum CompoundCombination	Head and Neck Squamous Cell Carcinoma	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID691 EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study. PMID 21048039 · Licitra et al., 2011 · Open in CIViC	civic

EGFR Amplification1

Cetuximab + Fluorouracil + Platinum CompoundCombination

Head and Neck Squamous Cell Carcinoma

Predictive

Does Not Support Sensitivity Response

accepted

EID691

EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study.

PMID 21048039 · Licitra et al., 2011 · Open in CIViC

civic

BIRC5 NUCLEAR EXPRESSION1
Platinum Compound + Taxane CompoundCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID874 Patients with nuclear survivin (BIRC5) expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P < 0.001) in a retrospective anal… (full text at CIViC) PMID 24961465 · Wu et al., 2014 · Open in CIViC	civic

BIRC5 NUCLEAR EXPRESSION1

Platinum Compound + Taxane CompoundCombination

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID874

Patients with nuclear survivin (BIRC5) expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P < 0.001) in a retrospective anal… (full text at CIViC)

PMID 24961465 · Wu et al., 2014 · Open in CIViC

civic

ERCC1 Underexpression2
Platinum Compound	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID6430 In this study, the goal was to study the predictive effect of ERCC1 expression to platinum based chemotherapy in Chinese patients with Non-small cell lung cancer (NSCLC). Of the patients that did not … (full text at CIViC) PMID 19488864 · Wang et al., 2010 · Open in CIViC	civic
〃	Ovarian CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID10146 Ovarian epithelial tumours (n=235) were used to create TMAs and IHC results were scored for ERCC1 (n=114 low, n=121 high). For platinum sensitive patients (n=250 in supplementary table, but not all ha… (full text at CIViC) PMID 30797591 · Mesquita et al., 2019 · Open in CIViC	civic

ERCC1 Underexpression2

Platinum Compound

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID6430

In this study, the goal was to study the predictive effect of ERCC1 expression to platinum based chemotherapy in Chinese patients with Non-small cell lung cancer (NSCLC). Of the patients that did not … (full text at CIViC)

PMID 19488864 · Wang et al., 2010 · Open in CIViC

civic

〃

Ovarian CarcinomaALIAS

Predictive

Supports Sensitivity Response

accepted

EID10146

Ovarian epithelial tumours (n=235) were used to create TMAs and IHC results were scored for ERCC1 (n=114 low, n=121 high). For platinum sensitive patients (n=250 in supplementary table, but not all ha… (full text at CIViC)

PMID 30797591 · Mesquita et al., 2019 · Open in CIViC

civic

RRM1 Underexpression1
Gemcitabine + Platinum CompoundCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID6434 A correlation was observed between the expression levels of ERCC1, RRM1, and XPD across all patients. In patients with non small cell lung cancer, patients in the bottom quartertile of RRM1 levels ha… (full text at CIViC) PMID 15217961 · Rosell et al., 2004 · Open in CIViC	civic

RRM1 Underexpression1

Gemcitabine + Platinum CompoundCombination

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID6434

A correlation was observed between the expression levels of ERCC1, RRM1, and XPD across all patients. In patients with non small cell lung cancer, patients in the bottom quartertile of RRM1 levels ha… (full text at CIViC)

PMID 15217961 · Rosell et al., 2004 · Open in CIViC

civic

WEE1 RS39103841
Gemcitabine + Platinum CompoundCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID814 The presence of the WEE1 polymorphism rs3910384 correlated with OS and PFS of NSCLC patients treated with platinum-based chemotherapy. Especially the combination of two DNA-damaging agents was associa… (full text at CIViC) PMID 26057002 · Liu et al., 2015 · Open in CIViC	civic

WEE1 RS39103841

Gemcitabine + Platinum CompoundCombination

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID814

The presence of the WEE1 polymorphism rs3910384 correlated with OS and PFS of NSCLC patients treated with platinum-based chemotherapy. Especially the combination of two DNA-damaging agents was associa… (full text at CIViC)

PMID 26057002 · Liu et al., 2015 · Open in CIViC

civic

BRCA1 Underexpression1
Platinum Compound + Taxane CompoundCombination	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID942 Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%C… (full text at CIViC) PMID 21920589 · Carser et al., 2011 · Open in CIViC	civic

BRCA1 Underexpression1

Platinum Compound + Taxane CompoundCombination

Malignant Ovarian Neoplasm

Predictive

Supports Sensitivity Response

accepted

EID942

Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%C… (full text at CIViC)

PMID 21920589 · Carser et al., 2011 · Open in CIViC

civic

BRCA2 Mutation3
Platinum Compound	Malignant Pancreatic Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID5916 Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=2… (full text at CIViC) PMID 25072261 · Golan et al., 2014 · Open in CIViC	civic
〃	Ovarian Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID1530 In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC	civic
〃	Ovarian Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID1532 In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC	civic

BRCA2 Mutation3

Platinum Compound

Malignant Pancreatic Neoplasm

Predictive

Supports Sensitivity Response

accepted

EID5916

Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=2… (full text at CIViC)

PMID 25072261 · Golan et al., 2014 · Open in CIViC

civic

〃

Ovarian Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID1530

In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0… (full text at CIViC)

PMID 24240112 · Pennington et al., 2014 · Open in CIViC

civic

〃

Ovarian Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID1532

In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.… (full text at CIViC)

PMID 24240112 · Pennington et al., 2014 · Open in CIViC

civic

BRCA1 Mutation2
Platinum Compound	Ovarian Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID1529 In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC	civic
〃	Ovarian Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID1531 In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC	civic

BRCA1 Mutation2

Platinum Compound

Ovarian Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID1529

PMID 24240112 · Pennington et al., 2014 · Open in CIViC

civic

〃

Ovarian Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID1531

PMID 24240112 · Pennington et al., 2014 · Open in CIViC

civic

AURKA Overexpression1
Platinum Compound	Ovarian Serous AdenocarcinomaALIAS	Predictive	B	Supports Resistance	3	accepted	EID1650 A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P = 0.001; HR 0.14) and platinum therapy resistance … (full text at CIViC) PMID 27209210 · Mignogna et al., 2016 · Open in CIViC	civic

AURKA Overexpression1

Platinum Compound

Ovarian Serous AdenocarcinomaALIAS

Predictive

Supports Resistance

accepted

EID1650

A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P = 0.001; HR 0.14) and platinum therapy resistance … (full text at CIViC)

PMID 27209210 · Mignogna et al., 2016 · Open in CIViC

civic

XRCC2 Deletion1
Platinum Compound	Gastrointestinal CarcinomaUNRESOLVED	Predictive	C	Supports Sensitivity Response	2	rejected	EID13254 A patient with a gastrointestinal malignancy lacking BRCA1/2 alterations had a homozygous XRCC2 deletion, accompanied by loss of two of three XRCC3 copies, high HRD score (35), high SBS3 exposure (0.0… (full text at CIViC) PMID 36964191 · Tsang et al., 2023 · Open in CIViC	civic

XRCC2 Deletion1

Platinum Compound

Gastrointestinal CarcinomaUNRESOLVED

Predictive

Supports Sensitivity Response

rejected

EID13254

A patient with a gastrointestinal malignancy lacking BRCA1/2 alterations had a homozygous XRCC2 deletion, accompanied by loss of two of three XRCC3 copies, high HRD score (35), high SBS3 exposure (0.0… (full text at CIViC)

PMID 36964191 · Tsang et al., 2023 · Open in CIViC

civic